Phase 2 study of alemtuzumab and dose-adjusted EPOCH-R in relapsed or refractory aggressive B-cell lymphomas. Lakhotia R, Melani C, Dunleavy K, Pittaluga S, et al. Leuk Lymphoma 2025;66:1088-1099.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Lakhotia R, Melani C, Dunleavy K, Pittaluga S, et al. Phase 2 study of alemtuzumab and dose-adjusted EPOCH-R in relapsed or refractory aggressive B-cell lymphomas. Leuk Lymphoma 2025;66:1088-1099.
PMID: 39899393